Row 1: K Page, J Kaplan, E Stalets
Row 2: R Chima, L Doughty, B Varisco
Row 3: D Wheeler, H Wong, K Tegtmeyer, R Basu
Studying pediatric septic shock
Jennifer Kaplan, MD, MS, received an Investigational New Drug approval from the Food and Drug Administration to conduct a Phase-1 trial of PPAR-gamma agonism in pediatric septic shock. This study reflects a natural progression of basic science research efforts in the division. The concept of PPAR-gamma agonism as therapeutic strategy in sepsis was demonstrated in pre-clinical studies led by Basilia Zingarelli, PhD. Kaplan’s Phase-1 study is the first direct translation of our basic science research to the bedside of critically ill children.
New director for basic research
Zingarelli, a nationally recognized researcher who has been with our Division since it formed in 1994, has been appointed director of basic research to provide expanded oversight for our growing research portfolio. She also has been named president - elect of the Shock Society, an international organization dedicated to improving the care of victims of trauma, shock, and sepsis.
Mechanisms of chronic lung disease
Brian Varisco, MD, who was recruited to Cincinnati Children’s to serve as a physician-scientist in pediatric critical care medicine, has secured K-level funding to continue his studies of the mechanisms of chronic lung disease. He achieved this milestone under the mentorship of Jeffrey Whitsett, MD, director of the Division of Pulmonary Biology and Chief of the Section of Neonatology, Perinatal and Pulmonary Biology.